Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: Potential and limits of its therapeutic efficacy

Journal of Immunology

Volumn 184, Issue 11, 2010, Pages 6124-6132

  Rolla, Simona ^a   Ria, Francesco ^b   Occhipinti, Sergio ^a   Di Sante, Gabriele ^b   Iezzi, Manuela ^c   Spadaro, Michela ^a   Nicolò, Chiara ^b   Ambrosino, Elena ^a   Merighi, Irene Fiore ^a   Musiani, Piero ^c   Forni, Guido ^a   Cavallo, Federica ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; ANTIBODY; CANCER VACCINE; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CARCINOMA IN SITU; CD8+ T LYMPHOCYTE; CELL CLONE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE DELETION; INVASIVE CARCINOMA; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE; THYMUS; ANIMAL; BAGG ALBINO MOUSE; CELL SEPARATION; DRUG ANTAGONISM; DRUG EFFECT; ELECTROPORATION; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MOUSE MUTANT; PROTO ONCOGENE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; CANCER VACCINES; CELL SEPARATION; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; GENES, ERBB-2; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, SCID; MICE, TRANSGENIC; RECEPTOR, ERBB-2; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; VACCINES, DNA;

EID: 77953438206     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901215     Document Type: Article

References (45)

1. Lollini, P. L., F. Cavallo, P. Nanni, and G. Forni. 2006. Vaccines for tumour prevention. Nat. Rev. Cancer 6: 204-216.
2. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400.
3. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
4. + regulatory T cells. J. Exp. Med. 202: 885-891.
5. + T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602.
6. Sica, A., T. Schioppa, A. Mantovani, and P. Allavena. 2006. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42: 717-727.
7. 2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67: 4507-4513.
8. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
9. 2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108: 228-237.
10. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
11. Boggio, K., G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, C. De Giovanni, et al. 1998. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188: 589-596.
12. Hüsemann, Y., J. B. Geigl, F. Schubert, P. Musiani, M. Meyer, E. Burghart, G. Forni, R. Eils, T. Fehm, G. Riethmüller, and C. A. Klein. 2008. Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68.
13. Rovero, S., A. Amici, E. Di Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P. L. Lollini, et al. 2000. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165: 5133-5142.
14. Nanni, P., G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, F. Cavallo, S. M. Pupa, I. Rossi, M. P. Colombo, C. Ricci, et al. 2001. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194: 1195-1205.
15. Rolla, S., C. Nicoló, S. Malinarich, M. Orsini, G. Forni, F. Cavallo, and F. Ria. 2006. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J. Immunol. 177: 7626-7633.
16. Quaglino, E., S. Rolla, M. Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P. L. Lollini, S. Lanzardo, G. Forni, R. Sanges, et al. 2004. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest. 113: 709-717.
17. Nanni, P., L. Landuzzi, G. Nicoletti, C. De Giovanni, I. Rossi, S. Croci, A. Astolfi, M. Iezzi, E. Di Carlo, P. Musiani, et al. 2004. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J. Immunol. 173: 2288-2296. (Pubitemid 39063084)
18. Pannellini, T., G. Forni, and P. Musiani. 2004. Immunobiology of her-2/neu transgenic mice. Breast Dis. 20: 33-42.
19. Ambrosino, E., M. Spadaro, M. Iezzi, C. Curcio, G. Forni, P. Musiani, W. Z. Wei, and F. Cavallo. 2006. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 66: 7734-7740.
20. Melani, C., C. Chiodoni, G. Forni, and M. P. Colombo. 2003. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102: 2138-2145.
21. Park, J. M., M. Terabe, D. D. Donaldson, G. Forni, and J. A. Berzofsky. 2008. Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol. Immunother. 57: 907-912.
22. Quaglino, E., M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S. M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, et al. 2004. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 64: 2858-2864.
23. Spadaro, M., E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W. Z. Wei, P. Musiani, P. L. Lollini, et al. 2005. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11: 1941-1952.
24. Rolla, S., C. Marchini, S. Malinarich, E. Quaglino, S. Lanzardo, M. Montani, M. Iezzi, M. Angeletti, G. Ramadori, G. Forni, et al. 2008. Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum. Gene Ther. 19: 229-240.
25. Ritchie, D. S., I. F. Hermans, J. M. Lumsden, C. B. Scanga, J. M. Roberts, J. Yang, R. A. Kemp, and F. Ronchese. 2000. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J. Immunol. Methods 246: 109-117.
26. Nagata, Y., R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, K. Furukawa, H. Nakamura, K. Furukawa, T. Kanematsu, and H. Shiku. 1997. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159: 1336-1343.
27. Ria, F., A. Gallard, C. R. Gabaglia, J. C. Guéry, E. E. Sercarz, and L. Adorini. 2004. Selection of similar naive T cell repertoires but induction of distinct T cell responses by native and modified antigen. J. Immunol. 172: 3447-3453.
28. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 174: 4228-4236.
29. + T cell response in vivo. J. Exp. Med. 192: 1719-1730.
30. Curcio, C., A. S. Khan, A. Amici, M. Spadaro, E. Quaglino, F. Cavallo, G. Forni, and R. Draghia-Akli. 2008. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther. 15: 108-114.
31. Sakai, Y., B. J. Morrison, J. D. Burke, J. M. Park, M. Terabe, J. E. Janik, G. Forni, J. A. Berzofsky, and J. C. Morris. 2004. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64: 8022-8028.
32. McMahan, R. H., and J. E. Slansky. 2007. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin. Cancer Biol. 17: 317-329.
33. Kedl, R. M., W. A. Rees, D. A. Hildeman, B. Schaefer, T. Mitchell, J. Kappler, and P. Marrack. 2000. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 192: 1105-1113.
34. Block, M. S., M. J. Hansen, V. P. Van Keulen, and L. R. Pease. 2003. MHC class I gene conversion mutations alter the CD8 T cell repertoire. J. Immunol. 171: 4006-4010.
35. Lanzavecchia, A. 2002. Lack of fair play in the T cell response. Nat. Immunol. 3: 9-10.
36. Jacob, J. B., Y. C. Kong, C. Meroueh, D. P. Snower, C. S. David, Y. S. Ho, and W. Z. Wei. 2007. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res. 67: 7020-7027.
37. Cappello, P., F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P. L. Lollini, A. Amici, E. Di Carlo, P. Musiani, M. Giovarelli, and G. Forni. 2003. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 63: 2518-2525.
38. Cavallo, F., R. Offringa, S. H. van der Burg, G. Forni, and C. J. Melief. 2006. Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 90: 175-213.
39. + regulatory T cell function. Science 322: 271-275.
40. Lustgarten, J., A. L. Dominguez, and C. Pinilla. 2006. Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope. J. Immunol. 176: 1796-1805.
41. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
42. Kim, P. S., T. D. Armstrong, H. Song, M. E. Wolpoe, V. Weiss, E. A. Manning, L. Q. Huang, S. Murata, G. Sgouros, L. A. Emens, et al. 2008. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J. Clin. Invest. 118: 1700-1711.
43. Jain, R. K. 2001. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46: 149-168.
44. Gade, T. P., I. M. Buchanan, M. W. Motley, Y. Mazaheri, W. M. Spees, and J. A. Koutcher. 2009. Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors. Clin. Cancer Res. 15: 247-255.
45. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601.